Searched for
DIABETES DRUG
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruptionDr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...- Beauty firms chase 'Ozempic face' market as weight-loss drugs boomGalderma, Natura, and L'Oreal are developing treatments for consumers experiencing facial sagging due to rapid weight loss. These companies...
- As weight-loss drug users turn to dietary supplements, doctors, regulators raise flagsThe growing use of GLP-1 weight-loss drugs such as Ozempic and Wegovy is driving demand for dietary supplements in the US, as users seek to...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...
- Bollywood actor Imran Khan, 43, says he follows two habits to be fit. One of them can delay ageing, reduce risk of heart disease, says scienceImran Khan made his Bollywood debut in the 2008 romantic comedy Jaane Tu Ya Jaane Na, where he appeared alongside Genelia D’Souza. He went ...
- GLP-1 and fertility: Could weight-loss medicines help women conceive? Here's what new reports revealinsulin resistance can disrupt reproductive hormones. For women with polycystic ovary syndrome (PCOS), ovulation may become irregular. Gett...
- Ministry of Science signs MoU with Peptris for collab in AI-based drug discovery and developmentThe Ministry of Science has entered into a partnership with Peptris Technologies to bolster drug development under the initiative called VI...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- WHO says medicines, surgery not first-line treatment for childhood obesityThe World Health Organization has released guidelines on treating obesity among children and adolescents. It emphasizes structured diets, p...
- ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...
- From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to IndiaIndia’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to la...
- 2026 Nobel Prize Predictions: From GLP-1 drugs and CAR-T therapy to gene editing, these breakthroughs could take centre stagePredictions for the 2026 Nobel Prizes in science highlight significant contributions in areas like GLP-1 research and cancer therapies. Car...
- ChrysCapital to take minority stake in Linux laboratoriesLinux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involv...
- Who is Veeramachineni Ramakrishna? Famous social media personality known for his VRK diet, booked in fake-doctor fraud case after law student hospitalized following his dietHyderabad police have registered a case against Veeramachineni Ramakrishna, also known as VRK, and Dr. Koteshwara Rao. These individuals fa...
- Women tip the scale as weight-loss boom reaches tier-II citiesWhile startups such as General Catalyst-backed Voy and Mumbai-based Metago are seeing higher demand from women, Elevate Now, backed by Tita...
- Virtual pharma API firm HRV preparing for IPO, DRHP likely in H1 of 2027: SourcesHRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs...
- GLP-1 users are suing over vision loss: What does the evidence really show?Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugsFacing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...
- ENTOD Pharmaceuticals secures patent for its insulin eye dropCurrently at the pre-clinical stage of development, the patented insulin eye drops are being investigated as a potential novel therapeutic ...
Load More
